IP Library › Granted Patent US 7,931,900
Granted Patent B2
US 7,931,900 · App. 12/277,030 · Granted Apr 26, 2011

Method for the treatment of multiple sclerosis by inhibiting IL-17 activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,931,900
App. No.
12/277,030
Granted
Apr 26, 2011
Kind
B2
Abstract

The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.

Claims (4)

1. A method for the treatment of multiple sclerosis (MS) comprising administering to a patient in need thereof a therapeutically effective amount of a neutralizing anti-IL-17 antibody or a neutralizing anti-IL-17 antibody fragment.

2. The method according to claim 1 , wherein the neutralizing antibody or neutralizing antibody fragment is monoclonal, polyclonal, chimeric, humanized, or bispecific.

3. The method according to claim 1 , wherein the neutralizing antibody fragment is a Fab, Fab′, F(ab′) 2 , scFv or epitope binding fragment.

4. The method according to claim 1 , wherein the neutralizing antibody or neutralizing antibody fragment is conjugated to one or more effector molecule(s).

Assignments (2)
CONFIRMATORY ASSIGNMENT Recorded Jun 10, 2016
From: UCB PHARMA, S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 038953/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2010
From: CELLTECH R&D LIMITED
To: UCB PHARMA S.A.
Reel/Frame 025415/0219 →